Gökçen KARTAL ÖZTÜRK, Aykut EŞKİ, Figen ÇELEBİ ÇELİK, Seçil CONKAR, Figen GÜLEN, Esen DEMİR, Ahmet KESKİNOĞLU

Prospective evaluation of vascular changes in acute respiratory infections in children with cystic fibrosis

Background/aim: Acute exacerbations and chronic inflammation are risk factors for cardiovascular disease CVD in cystic fibrosis CF patients. The aim of this study was to investigate the effects of acute exacerbation therapy on arterial stiffness in children with CF. Materials and methods: Augmentation index Aix and pulse wave velocity PWV were measured before and after treatment and 1 month after the end of treatment in patients with acute exacerbation. The relationship between hemodynamic measurements and c-reactive protein CRP and pulmonary function tests PFTs was investigated. Results: Measurements before and after treatment were evaluated in 27 patients and were repeated in 21 patients who were clinically stable 1 month following acute exacerbation. There was a significant decrease in CRP and an increase in spirometry parameters after treatment. While no significant difference was found between PWV P = 0.33 , a significant difference for Aix before 41.95 ± 12.96% and after 30.95 ± 11.47% treatment and before treatment and stable clinical condition 34.19 ± 14.36% was obtained P =0.00, and P =0.01, respectively . No significant difference in heart rate and other hemodynamic measurements was found. Pretreatment Aix is associated with poor clinical condition PFTs, BMI, and clinical score and systemic inflammation CRP P

Keywords:

Cystic fibrosis, arterial stiffness, pulse wave velocity analysis, augmentation index, pulmonary exacerbation,

___

1. Mills NL, Miller JJ, Anand A, Robinson SD, Frazer GA et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 2008; 63(4): 306-311. doi: 10.1136/thx.2007.083493
2. Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005; 46(1): 194-199. doi: 10.1161/01. HYP.0000168055.89955.db
3. Schillaci G, De Socio GV, Pucci G, Mannarino MR, Helou J et al. Aortic stiffness in untreated adult patients with human immunodeficiency virus infection. Hypertension 2008; 52(2): 308-313. doi: 10.1161/HYPERTENSIONAHA.108.114660
4. Hull JH, Garrod R, Ho TB, Knight RK, Cockcroft JR et al. Increased augmentation index in patients with cystic fibrosis. The European Respiratory Journal 2009; 34(6): 1322-1328. doi: 10.1183/09031936.00044009
5. Urbina EM, Williams RV, Alpert BS, Collins BT, Daniels RN et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension. 2009; 54: 919-950. doi: 10.1161/ HYPERTENSIONAHA.109.192639
6. Fabbri LM, Beghe B, Agusti A. Cardiovascular mechanisms of death in severe COPD exacerbation: time to think and act beyond guidelines. Thorax 2011; 66(9): 745-747. doi: 10.1136/ thoraxjnl-2011-20040
7. Hull JH, Garrod R, Ho TB, Knight RK, Cockcroft JR et al. Dynamic vascular changes following intravenous antibiotics in patients with cystic fibrosis. The Journal of Cystic Fibrosis 2013; 12(2): 125-129. doi: 10.1016/j.jcf.2012.07.004
8. Kartal Öztürk G, Conkar S, Eşki A, Gülen F, Keskinoğlu A et al. Evaluation of increased arterial stiffness in pediatric patients with cystic fibrosis by augmentation index and pulse wave velocity analysis. Pediatric Pulmonology 2020; 55: 1147-1153. doi: 10.1002/ppul.24688
9. Neyzi O, Bundak R, Gökçay G, Günöz H, Furman A et al. Reference values for weight, height, head circumference, and body mass index in Turkish children. Journal of Clinical Research in Pediatric Endocrinology 2015; 7(4): 280-93. doi: 10.4274/jcrpe.2183
10. Shwachman H, Kulczycki LL. Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteenyear period. The American Journal of Diseases of Children 1958; 96(1): 6-15. doi: 10.1001/archpedi.1958.02060060008002
11. Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. The Canadian Journal of Cardiology 2011; 27(2): 174-182. doi: 10.1016/j.cjca.2010.12.040
12. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. The New England Journal of Medicine 2004; 351(25): 2611-2618. doi: 10.1056/NEJMoa041747
13. Reverri EJ, Morrissey BM, Cross CE, Steinberg FM. Inflammation, oxidative stress, and cardiovascular disease risk factors in adults with cystic fibrosis. Free Radical Biology & Medicine 2014; 76: 261-277. doi: 10.1016/j.freeradbiomed.2014.08.005
14. van der Veen BS, de Winther MP, Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxidants & Redox Signaling 2009; 11(11): 2899-2937. doi: 10.1089/ARS.2009.2538
15. Quinn K, Henriques M, Parker T, Slutsky AS, Zhang H. Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases. The American Journal of PhysiologyHeart and Circulatory Physiology 2008; 295(5): 1817-1824. doi: 10.1152/ajpheart.00472.2008
16. Range SP, Dunster C, Knox AJ, Kelly FJ. Treatment of pulmonary exacerbations of cystic fibrosis leads to improved antioxidant status. The European Respiratory Journal 1999; 13(3): 560-564. doi: 10.1183/09031936.99.13356099
17. Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A et al. Oxidative stress and antioxidant therapy in cystic fibrosis. Biochimica et Biophysica Acta 2012; 1822(5): 690-713. doi: 10.1016/j.bbadis.2011.12.012
18. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. The European Heart Journal 2006; 27(21): 2588-2605. doi: 10.1093/eurheartj/ ehl254
19. Urbina EM, Williams RV, Alpert BS, Collins RT, Daniels SR et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009; 54(5): 919-950. doi: 10.1161/ HYPERTENSIONAHA.109.192639
20. McEniery CM, Yasmin, Maki-Petaja KM, McDonnell BJ, Munnery M et al. The impact of cardiovascular risk factors on aortic stiffness and wave reflections depends on age: the Anglo-Cardiff Collaborative Trial (ACCT III). Hypertension 2010; 56(4): 591-597. doi: 10.1161/HYPERTENSIONAHA.110.156950
21. Maki-Petaja KM, Hall FC, Booth AD, Wallace SM, Yasmin, Bearcroft PW et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by antitumor necrosis factor-alpha therapy. Circulation 2006; 114(11): 1185-1192. doi: 10.1161/CIRCULATIONAHA.105.601641
22. Klocke R, Cockcroft JR, Taylor GJ, Hall IR, Blake DR. Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. Annals of the Rheumatic Diseases 2003; 62(5): 414-418. doi: 10.1136/ard.62.5.414
23. Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005; 112(14): 2193-2200. doi: 10.1161/CIRCULATIONAHA.105.535435
24. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. The New England Journal of Medicine 2002; 347(20): 1557-1565. doi: 10.1056/NEJMoa021993
25. Booth AD, Wallace S, McEniery CM, Yasmin, Brown J et al. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis & Rheumatology 2004; 50(2): 581-588. doi: 10.1002/art.20002
26. Van Doornum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2004; 63(12): 1571-1575. doi: 10.1136/ard.2003.018333